期刊文献+

氨磺必利与利培酮治疗首发精神分裂症的效果比较 被引量:2

下载PDF
导出
摘要 目的:观察利培酮与氨磺必利治疗首发精神分裂症患者的临床效果。方法:选取治疗的60例首发精神分裂症患者,按照随机数字表法将其分为对照组和观察组,每组30例。对照组予利培酮口服治疗,观察组予氨磺必利口服治疗,比较两组临床疗效,阳性与阴性症状量表(PANSS)各项分值和总分,以及不良反应发生率。结果:观察组临床总有效率为90.00%,高于对照组的66.67%,差异有统计学意义(P<0.05);治疗后两组PANSS各项评分及总分均较治疗前降低,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:氨磺必利治疗首发精神分裂症患者的效果优于利培酮效果,可以有效控制临床症状,值得推荐。
作者 张永超
出处 《中国民康医学》 2019年第19期83-84,共2页 Medical Journal of Chinese People’s Health
  • 相关文献

参考文献5

二级参考文献49

  • 1世界卫生组织.ICD-10精神与行为障碍分类:临床描述与诊断要点[M].范肖东,汪向东,于欣,等,译.北京:人民卫生出版社,1993.
  • 2中华医学会精神科分会.中国精神障碍分类与诊断标准第3版(CCMD-3)[M].济南:山东科学技术出版社,2001.91-103.
  • 3Patel JK, Buckley PF, Woolson S, et al. Metabolic profiles of sec- ond-generation antipsychotics in early psychosis: findings from the CAFE study [ J]. Schizophr Res, 2009, 111 ( 1 - 3) : 9 - 16.
  • 4Mcevoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CAT- IE) Schizophrenia Trial and comparison with national estimates from NHANES HI [ J]. Schizophr Res, 2005, 80( 1 ) : 19 - 32.
  • 5Meyer JM, Nasrallah HA, Mcevoy JP, et al. The Clinical Antipsy- chotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the meta- bolic syndrome [ J]. Schizophr Res, 2005, 80( l ) : 9 - 18.
  • 6Brown S. Excess mortality of schizophrenia. A meta-analysis I J]. Br J Psychiatry, 1997, 171:502 -508.
  • 7Colton CW, Manderscheid RW. Congruencies in increased mortali- ty rates, years of potential life lost, and causes of death among pub- lic mental health clients in eight states [ J]. Prev Chronic Dis, 2006, 3(2) : A42.
  • 8Saari K, Koponen H, Laitinen J, et al. Hyperlipidemia in persons u- sing antipsychotic medication: a general population-based birth co- hort study [J]. J Clin Psychiatry, 2004, 65(4) : 547 -550.
  • 9Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizo- phrenia or schizoaffective disorder [ J]. Am J Psychiatry, 2004, 16l (10) : 1837 - 1847.
  • 10Simpson GM, Weiden P, Pigott T, et al. Six-month, blinded, multi- center continuation study of ziprasidone versus olanzapine in schiz- ophrenia [J]. Am J Psychiatry, 2005, 162(8) : 1535 - 1538.

共引文献149

同被引文献21

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部